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ABSTRACT:

Introduction: Pharmacokinetic and pharmacodynamic drug interactions (DIs) can occur between
antiepileptics (AEDs) and second-generation antipsychotics (SGAPs). Some AED and SGAP
pharmacodynamic mechanisms are poorly understood. AED-SGAP combinations are used for treating comorbid illnesses or increasing efficacy, particularly in bipolar disorder.

Areas covered: This article provides a comprehensive review of the interactions between antiepileptics
and second-generation antipsychotics. The authors cover pharmacokinetic AED-SGAP DI studies, the
newest drug pharmacokinetics in addition to the the limited pharmacodynamic DI studies.

Expert opinion: Dosing correction factors and measuring SGAP levels can help to compensate for the
inductive properties of carbamazepine, phenytoin, phenobarbital and primidone. More pharmacokinetic
studies are needed to establish the clinical relevance of combining: i) AED strong inducers with
amisulpride, asenapine, iloperidone, lurasidone and paliperidone; ii) valproate with aripiprazole,
asenapine, clozapine and olanzapine; and iii) high doses of oxcarbazepine (≥ 1500 mg/day) or topiramate
(≥ 400 mg/day) with aripiprazole, lurasidone, quetiapine, risperidone, asenapine and olanzapine. Two
pharmacodynamic DIs are beneficial: i) valproate-SGAP combinations may have additive effects in
bipolar disorder, and ii) combining topiramate or zonisamide with SGAPs may decrease weight gain.
Three pharmacodynamic DIs contributing to decreased safety are common: sedation, weight gain and
swallowing disturbances. A few AED-SGAP combinations may increase risk for osteoporosis or nausea.
Three potentially lethal but rare pharmacodynamic DIs include pancreatitis, agranulocytosis/leucopenia
and heat stroke. Collaboration from all interested parties including: i) drug agencies and pharmaceutical
companies; ii) clinicians using these combinations; iii) researchers with expertise in meta-analyses,
pharmacoepidemiology, and DI pharmacology; and iv) grant agencies) is needed to progress in this area.
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Highlights box
-Drug-drug interactions (DIs) between antiepileptics (AEDs) and second-generation antipsychotics
(SGAPs) are frequently clinically relevant.
-More pharmacokinetic DI studies are needed for: i) AED strong inducers with amisulpride, asenapine,
iloperidone, lurasidone and paliperidone; ii) valproate with aripiprazole, asenapine, clozapine and
olanzapine; and iii) high doses of oxcarbazepine (≥ 1500 mg/day) or topiramate (≥ 400 mg/day) with
SGAPs dependent on CYP3A4 (aripiprazole, lurasidone, quetiapine and risperidone) or UGTs (asenapine
and olanzapine) for their metabolism.
-The pharmacodynamic science of AED-SGAP DIs is in its infancy.
-Possible beneficial pharmacodynamic DIs are: i) valproate-SGAP combinations for bipolar disorder, and
ii) combining topiramate or zonisamide with SGAPs to decrease weight gain.
-Pharmacodynamic AED-SGAP DIs may increase risk for sedation, weight gain, swallowing
disturbances, osteoporosis, nausea, pancreatitis, agranulocytosis/leucopenia and heat stroke.
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1. Introduction
Antiepileptics (AED) can be divided into first-generation AEDs (FGAEDs) and second-generation
AEDs (SGAEDs). Their clinically relevant drug interactions (DIs) with antipsychotics (APs) are the focus
of this review. APs can similarly be divided into first-generation APs (FGAPs) and second-generation
antipsychotics APs (SGAPs). Prior DI reviews [1, 2] included a particularly comprehensive review [2],
but since its publication [2], no studies of clinically relevant DIs between FGAPs and AEDs have
appeared. This article provides an updated review of clinically relevant DIs between AEDs and SGAPs.
The introduction provides a brief description of AEDs, SGAPs, their pharmacokinetics, their
pharmacodynamics and co-prescription.
1.1. AEDs
AED drugs are widely used not only for the treatment of epilepsy, but also for the management of
a variety of non-epileptic neurological conditions and psychiatric disorders [3]. The FGAEDs include
carbamazepine, ethosuximide, phenytoin, phenobarbital, primidone and valproate (Table 1). The
SGAEDs include eslicarbazepine, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam,
oxcarbazepine, pregabalin, retigabine, rufinamide, stiripentol, tiagabine, topiramate, vigabatrin and
zonisamide (Table 1). Some SGAEDs (eslicarbazepine, retigabine, stiripentol, and vigabatrin) are not
marketed in the US.

When compared with FGAEDs, most SGAEDs except for felbamate are

characterized by better safety profiles with fewer adverse drug reactions (ADRs) and less DI risk than
FGAEDs. The only FGAED that continues to be a first-line choice AED may be valproate, but its
teratogenicity risk is contributing to its decreased use in females of fertile age. There are no definitive
studies comparing the efficacy of all FGAEDs and the most important SGAEDs in the same study, but in
the developed countries SGAEDs, particularly lamotrigine, levetiracetam, and oxcarbazepine, have
partially substituted for FGAEDs due to their better safety profiles [4,5].
1.2. SGAPs
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In recent years, SGAPs (amisulpride, aripiprazole, asenapine, clozapine, iloperidone, lurasidone,
olanzapine, paliperidone, quetiapine, risperidone, and ziprasidone) (Table 2) have progressively replaced
FGAPs in the developed countries due to better safety profiles for reversible extrapyramidal symptoms
and tardive dyskinesia, and better marketing. SGAPs are widely used not only for schizophrenia and
bipolar disorder, but for adjuvant treatment of major depressive disorder, psychosis and behavioral
disorders in dementia, psychosis associated with Parkinson's disease, resistant obsessive-compulsive
disorder, aggressive behavior and irritability in autism spectrum disorders [6].
1.3. Pharmacokinetics
There are two basic types of DIs, pharmacokinetic and pharmacodynamic DIs. Pharmacokinetic
DIs can be established and quantified by the study of changes in plasma drug concentrations, usually
called therapeutic drug monitoring (TDM), and can occur at absorption, distribution, metabolism or
excretion of a drug and/or its metabolite(s). The most important pharmacokinetic DIs are the metabolic
DIs. This subsection in pharmacokinetics focuses on the metabolism of AEDs and SGAPs and the clinical
consequences of pharmacokinetic DIs. Figure 1 discusses the possibility of non-metabolic
pharmacokinetic DIs based on the P-glycoprotein (P-gp) or protein binding [7].
1.3.1. Metabolism
The cytochrome P450 (CYP) isoenzymes are the most important oxidative enzymes; the uridine
diphosphate glucuronosyltransferases (UGTs) are the most important conjugation enzymes. CYP
substrates, inhibitors and inducers are well established while those for UGTs are less known.
1.3.1.1. AED metabolism. FGAEDs are extensively metabolized in the liver by CYPs and UGTs (Table
1). By contrast [8], many SGAPs have less propensity for pharmacokinetic DIs because they are not
metabolized at all (gabapentin, pregabalin and vigabatrin) and are renally cleared, or undergo minimal
hepatic biotransformation (levetiracetam and rufinamide) (Table 1). Four FGAEDs, namely
carbamazepine, phenytoin, phenobarbital and primidone, induce the activity of multiple enzymes
including CYPs, UGTs and epoxide hydrolase (Table 3) [9]. Once steady state is present, inducers need a
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few weeks, usually 2-4 weeks, to reach maximum effects and to disappear. Thus, sometimes it takes up to
one month to see the whole effect of adding or discontinuing an inducer. Among FGAEDs, valproate is a
broad-spectrum inhibitor of various drug-metabolizing enzymes including CYP2C9 and UGTs. Some of
the newer AEDs may at times act as enzyme inhibitors. Eslicarbazepine, felbamate, oxcarbazepine and
topiramate are weak inhibitors of CYP2C19, while stiripentol is a potent inhibitor of CYP1A2, CYP2C19,
CYP2D6 and CYP3A4. Eslicarbazepine, felbamate, oxcarbazepine (particularly at dosages ≥ 1500
mg/day) [10], rufinamide and topiramate (particularly at dosages ≥ 400 mg day) [11] can induce the
activity of CYP3A4 and possibly some UGTs.
1.3.1.2. SGAP metabolism. With the exception of amisulpride and paliperidone, SGAPs are targets of
metabolic DIs because they undergo extensive hepatic biotransformation via CYPs and UGTs, which are
highly inducible and readily inhibited. SGAPs appear not to be clinically relevant inhibitors or inducers
[12] (see competitive inhibition in footnote 2, Table 2).
1.3.2. Clinical consequence of pharmacokinetic DIs
Metabolic DIs change the concentration-dose (C/D) ratio that reflects how the drug is cleared from
the body at steady state. For SGAPs, the C/D ratio can be represented by a line (linear kinetics).
Complicating predictions, some AEDs do not follow linear kinetics (Table 1), thus their C/D ratios may
change with different concentrations. Inhibitors increase the C/D ratio (lower substrate doses provide the
same concentration) while inducers decrease the C/D ratio (higher substrate doses are required to reach
the same concentration). Pharmacokinetic DI studies can be used to estimate correction factors, which are
>1 in inducers and <1 in inhibitors. A correction factor of 2 indicates that you need to double the dose for
the same effect. A correction factor of 0.5 indicates that you need to halve the dose for the same effect.
The further the correction factor is from 1, the more relevant the DI may be. The therapeutic window or
index also determines the clinical relevance of correction factors. Failing to correct for the therapeutic
window after adding or discontinuing inducers or inhibitors may have much greater clinical consequences
in drugs with narrow therapeutic windows.
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1.4. Pharmacodynamics
Most articles reviewing DIs ignore pharmacodynamic mechanisms of AED and SGAP, which are
poorly understood. This subsection provides a very brief reference to the pharmacodynamics of AEDs
and SGAPs; they are described more comprehensively in Figures 2 to 5 and their detailed footnotes. At
the end of this section, a subsection comments on the types of pharmacodynamic DIs.
1.4.1. AED pharmacodynamics
Figure 2 summarizes the AED’s mechanism of action in epilepsy, bipolar disorder, anxiety, pain,
migraine prophylaxis and weight loss [3, 13-19]. Figure 3 summarizes the AED’s mechanism of action
associated with major safety issues [20-36].
1.4.2. SGAP pharmacodynamics
Figure 4 summarizes the SGAPs’ mechanism of action, explaining their efficacy in schizophrenia,
other psychoses and other psychiatric disorders [6, 37-42]. Many AP ADRs are explained by their
blockade of neurotransmitter receptors (Figure 5) [43-59].
1.4.3. Pharmacological knowledge and pharmacodynamic DIs
Pharmacodynamic DIs take place directly at the site of action of a drug or indirectly by interfering
with another physiological mechanism. They result in a modification of the pharmacological action of a
drug without any change in the plasma concentration and are more difficult to identify and measure than
pharmacokinetic DIs. These DIs can be additive (i.e., equal to the sum of the effects of the individual
drugs), synergistic (i.e., combined effects are greater than expected from the sum of individual effects) or
antagonistic (i.e., combined effects are less than additive) [9]. They can be associated with positive effects
(increased efficacy and/or safety) or negative effects (decreased efficacy and/or safety).
1.5. Co-prescription of AEDs and SGAPs
AEDs and SGAPs are often prescribed together because co-morbidities may occur: i) AEDs are
usually administered for prolonged periods in people with epilepsy and SGAPs may be needed to treat the
highly prevalent psychiatric disorders seen in people with epilepsy; ii) autism spectrum disorders are
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associated with very high risk of epilepsy, frequently with poor prognosis, and some SGAPs have been
approved in the US market for the treatment of irritability in children with these disorders (Figure 4); or
iii) AEDs may be used to treat non-epileptic conditions (e.g., neuropathic pain and migraine) in patients
taking SGAPs.
In other cases clinicians co-prescribed them to decrease ADRs (AED medications may be used to
treat seizures associated with some SGAPs, clozapine is particularly associated with dosage-related
seizures) or increase efficacy: several AEDs (carbamazepine, lamotrigine, and valproate) and SGAPs are
approved for bipolar disorder. Therefore, combinations of AEDs and SGAPs are increasingly used in the
management of bipolar disorder. Other AEDs are being studied as potential mood stabilizers
(oxcarbazepine and zonisamide). Other adjunctive therapies are less established as effective in the
literature including: i) valproate or carbamazepine added to SGAPs in people with schizophrenia or
schizoaffective disorder to better treat the psychosis or for the management of aggressive behaviors, and
ii) lamotrigine added to clozapine for the management of treatment-resistant schizophrenia.
In summary, 1) AEDs and SGAPs are frequently co-prescribed, 2) they have clinically relevant
DIs, and 3) there is no recent comprehensive review of this subject.

2. DI studies and their clinical relevance
This section provides a comprehensive review of DI studies including three sections that order
compounds alphabetically: 1) the metabolic DI studies, starting with a review of the effects of each AED
on each SGAP and then the effects of the SGAPs on the AEDs; 2) predictions of the metabolic DIs for
new AEDs and SGAPs; and 3) a review of the limited studies on pharmacodynamic DIs. Articles for this
review were obtained from a PubMed search with no time limit and through hand-searching of a number
of recent journals and recent reviews. Searches were performed for each of the AEDs and SGAPs. This
search was beyond the articles previously found and listed in the authors’ published literature reviews [9,
12] and DI studies.
2.1. Pharmacokinetic DI studies
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2.1.1. Carbamazepine
Carbamazepine is a powerful inducer of several drug-metabolizing enzymes including CYPs,
namely CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19, CYP3A4, as well as UGTs, such as
UGT1A1, UGT2B7, UGT2B15.
2.1.1.1. Carbamazepine on aripiprazole. Carbamazepine decreased the mean area under the curve (AUC)
of aripiprazole and dehydro-aripiprazole serum concentrations by 71% and 69%, respectively, in a study
of 30 mg/day of aripiprazole for 14 days and then 4-6 weeks of carbamazepine titrated to concentrations
of 8-12 g/mL [60]. Similarly, a study of 18 schizophrenia patients treated with aripiprazole found 400
mg/day of carbamazepine, administered for 1 week, caused a significant decrease in aripiprazole and
dehydro-aripiprazole concentrations by 64% and 68%, respectively [61]. A routine TDM study indicated
that carbamazepine lowered dose-adjusted concentrations of aripiprazole by 88% [62].
2.1.1.2. Carbamazepine on clozapine. In a TDM clozapine study, patients on carbamazepine had a mean
50% lower C/D ratio of clozapine than the monotherapy group [63]. In a comparison of the effects of
carbamazepine and oxcarbazepine on clozapine serum concentrations in 12 patients, Tiihonen et al. found
that the clozapine concentration was 47% lower with carbamazepine than with oxcarbazepine [64].
Carbamazepine’s inducing effect on CYP1A2- and CYP3A4-mediated clozapine metabolism probably
explains these results.
2.1.1.3. Carbamazepine on olanzapine. A DI study of 11 healthy volunteers assessed a single 10 mg
olanzapine dose before and after administration of carbamazepine 400 mg/day for 18 days [65].
Carbamazepine resulted in a 46% increase in olanzapine clearance and in a 34% decrease in its AUC. In
carbamazepine patients the median dose-normalized olanzapine concentrations were 36-71% lower than
in those in monotherapy according to TDM studies [66-69]. Specifically, Linnet and Olesen evaluated the
influence of carbamazepine on olanzapine glucuronidation in a TDM study [67]. Two median differences
were significant between 16 carbamazepine patients and 31 in monotherapy: i) free olanzapine C/D ratio
was 38% lower (3.6 nmol/l/mg versus 5.8 nmol/l/mg), and ii) glucuronidated fraction (79% versus 43%)
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[67]. Carbamazepine lowered free olanzapine concentration by increasing glucuronidation metabolism.
All of these studies clearly indicated that carbamazepine increases olanzapine metabolism by CYP1A2and UGT-induction.
2.1.1.4. Carbamazepine on paliperidone. CYP inhibitors or inducers were not expected to have a
significant influence on paliperidone metabolism but the US package insert describes 400 mg/day of
carbamazepine as decreasing the mean steady-state serum peak concentration (Cmax) and the AUC of
paliperidone by approximately 37%, due to a 35% increase in the renal clearance of paliperidone. This is
attributed to carbamazepine induction of the renal P-gp.
2.1.1.5. Carbamazepine on quetiapine. Carbamazepine (600 mg/day) decreased quetiapine Cmax by 80%
and AUC by 87% and increased oral clearance by a 7.5-fold increase in a pharmacokinetic study of 18
psychiatric patients [70]. TDM studies [71-74] provided similar results. In particular, in a large routine
TDM database, the mean quetiapine C/D ratio was 9 times lower (0.02 versus 0.18) and significantly
lower (95% confidence intervals 0.02-0.03 versus 0.17-0.19, p < 0.001) for the 39 carbamazepine-treated
patients versus the 1123 patients on quetiapine monotherapy [72]. The DI clinical implications were
demonstrated in three patients taking carbamazepine 400-800 mg/day in which serum quetiapine
concentrations could not be detected (<25 ng/mL) despite taking 700 mg/day [75]. These massive
pharmacokinetic changes are explained by the potent inducing effect of carbamazepine on CYP3A4mediated quetiapine metabolism.
2.1.1.6. Carbamazepine on risperidone. A case report first reported that serum risperidone active moiety
(risperidone and its pharmacologically active metabolite 9-hydroxy-risperidone) doubled after
carbamazepine discontinuation, leading to an ADR [76]. A subsequent study indicated that risperidone
moiety was approximately 1.4 times lower in 11 carbamazepine patients versus 23 patients on risperidone
alone [77]. In 5 patients assessed on and off carbamazepine co-medication, risperidone moiety was 1.5
times lower on carbamazepine [77]; in 11 other patients it was 1.8 times lower [78]. The clinical
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relevance of the increase in risperidone metabolism attributed to the carbamazepine CYP3A4-inducing
effects was demonstrated by an acute psychotic exacerbation in a case report [79].
2.1.1.7. Carbamazepine on ziprasidone. Carbamazepine (400 mg/day) lowered ziprasidone mean Cmax by
27% and mean AUC0-12h by 36% in 19 healthy volunteers taking 40 mg/day of ziprasidone [80].
Carbamazepine probably induced CYP3A4-mediated ziprasidone metabolism.
2.1.1.8. SGAPs on carbamazepine. Two weeks after the addition of risperidone (1 mg/day) the mean
steady-state carbamazepine concentrations mildly increased by 19% in 8 epileptic patients [81], probably
due to competitive inhibition of CYP3A4. Adding quetiapine led to a pharmacokinetic DI and ADRs in 2
patients [82], probably due to the competitive inhibition of CYP3A4.
2.1.2. Lamotrigine
Lamotrigine does not appear to be a CYP inhibitor or inducer but is a weak UGT inducer [9].
2.1.2.1. Lamotrigine on clozapine. A case report associated a clozapine ADR with a 3-fold increase in
serum clozapine concentrations when lamotrigine was added [83]. However two studies (a randomized
clinical trial [RCT] in 34 hospitalized treatment-resistant patients [84] and a pharmacokinetic study in 11
patients stabilized on clozapine [85]) found no serum clozapine concentration changes during lamotrigine
treatment up to 200 mg/day.
2.1.2.2. Lamotrigine on olanzapine. Although UGT1A4 metabolizes both lamotrigine and olanzapine, two
studies of healthy volunteers using low lamotrigine doses (50 and 200 mg/day) found no effects on
olanzapine pharmacokinetics [86, 87]. A mild (15%) but significant increase in steady-state olanzapine
serum concentration was found in 14 patients taking olanzapine (10-20 mg/day) after adding 100 mg/day
of lamotrigine [85]. By using a mixed model, Botts et al. confirmed that lamotrigine behaved as an
olanzapine inhibitor in smokers, increasing the C/D ratio by 35%, whereas the lamotrigine produced a
mild non-significant decrease in olanzapine C/D ratio in nonsmokers [69].
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2.1.2.3. Lamotrigine on quetiapine. A large TDM study reported a slight (17%) and significant 17%
decrease in quetiapine C/D ratio in 147 lamotrigine patients when 1123 were on quetiapine monotherapy
[62].
2.1.2.4. Lamotrigine and risperidone. An ADR case report described a 5-6-fold elevation in risperidone
levels after adding lamotrigine [88]. However, a study of 10 psychotic patients stabilized on risperidone
(3-6 mg/day), demonstrated that up to 200 mg/day of lamotrigine had no influence on serum risperidone
moiety [85].
2.1.2.5. SGAPs on lamotrigine. There was no influence on lamotrigine levels in: i) a TDM study (N=829)
with clozapine, risperidone or olanzapine co-prescription [89], and ii) an aripiprazole study with 30
mg/day in 18 bipolar patients [90].
2.1.3. Phenobarbital/phenytoin
Phenobarbital and phenytoin are considered powerful and promiscuous inducers of CYPs,
(including CYP1A2, CYP2C, and CYP3A4) as well as UGTs.
2.1.3.1. Phenobarbital/phenytoin on clozapine. Two patients had a psychotic exacerbation after adding
phenytoin, which decreased clozapine levels by 65-85% [91]. Lane et al. described a patient with a
remarkable elevation of clozapine levels 2 weeks after phenobarbital discontinuation [92]. Facciolà et al.
found that serum clozapine concentrations were significantly lower in 7 phenobarbital-treated patients
than in 15 monotherapy patients (232 ± 104 ng/ml versus 356 ± 13 ng/ml) and attributed this decrease to
CYP1A2- and CYP3A4-induction [93].
2.1.3.1. Phenytoin on quetiapine. Quetiapine clearance increased more than 5-fold from 80.3 ± 35.9 l/hr to
440 ± 214 l/hr when comparing 10 patients on 750 mg/day after receiving phenytoin (300 mg/day) [94].
2.1.4. Oxcarbazepine
Oxcarbazepine is a keto-analog of carbamazepine. Unlike carbamazepine, this AED seems to be a
modest CYP3A4 inducer [9]. As previously mentioned, carbamazepine was associated with lower
clozapine levels in 12 patients when compared with oxcarbazepine [64]. Minimal and not significant
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serum concentration modifications occurred after a 5-week treatment of oxcarbazepine (900-1200
mg/day) in psychotic patients stabilized on risperidone (2-6 mg/day; n=12) or olanzapine (5-20 mg/day;
n=13) [95].
2.1.5. Topiramate
Topiramate is a weak inhibitor of CYP2C19 and a weak inducer of CYP3A4 [9]. Adding up to
200 mg/day of topiramate brought no serum concentration modifications for clozapine (250-500 mg/day,
n=10), olanzapine (10-20 mg/day, n=12), risperidone (3-6 mg/day, n=9) or quetiapine (200-600 mg/day,
n=7) [96]. It cannot be ruled out that higher topiramate doses may have an inductive effect in these
SGAPs.
2.1.6. Valproate
Valproate has traditionally been considered a broad-spectrum metabolic enzyme inhibitor. It
inhibits CYP2C9 competitively, CYP2C19 and CYP3A4 weakly and has no effects on CYP1A2,
CYP2D6, and CYP2E1. It inhibits UGT enzymes (UGT1A4 and UGT2B7) [9]. A recent human
hepatocyte study surprisingly demonstrated that valproate may induce some enzymes (CYP3A4 and P-gp
gene expression) [97].
2.1.6.1. Valproate on aripiprazole. A decrease of 26% in the aripiprazole Cmax and of 24% in the
aripiprazole AUC with minimal effects on the active metabolite of aripiprazole after valproate addition
was found in an open study of 10 schizophrenia patients [98]. Similarly, in a TDM study aripiprazole C/D
was 24% lower in 7 patients co-medicated with valproate than in 23 on aripiprazole monotherapy [62].
Aripiprazole is a CYP3A4 and P-gp substrate; thus valproate may mildly induce CYP3A4 and/or P-gp.
Both can decrease intestine drug absorption.
2.1.6.2.Valproate on clozapine. Early studies provided conflicting findings of increases and decreases of
clozapine metabolism by valproate, which were unlikely to be clinically significant [reviewed by 99].
The three best studies [100-102] suggested that valproate might inhibit clozapine conversion to
norclozapine via CYP1A2 or CYP3A4. In contrast, Finley and Warner found in four male patients that

clozapine concentrations decreased by 41% when valproate was administered [103].
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By using a

statistical mixed model that estimated the effect sizes of co-medications on clozapine levels after
correcting for confounding variables, Diaz et al. found that valproate appeared to act as a clozapine
inhibitor in non-smokers and as an inducer in smokers [99]. These findings may account for the
inconsistent valproate results on clozapine metabolism.
2.1.6.3. Valproate on olanzapine. As valproate and olanzapine share common metabolic pathways, a
metabolic DI can occur. TDM studies found no valproate influence on olanzapine metabolism [69, 104].
However, in four patients stabilized on olanzapine, valproate (1000-2700 mg/day) decreased olanzapine
levels by 50% with a psychiatric deterioration in three of them [105]. Valproate co-administration (6002000 mg/day) was associated with a significant decrease in mean serum olanzapine concentrations from
32.9 ± 9.7 ng/mL at baseline to 27.4 ± 9.8 ng/mL at week 2, and to 26.9 ± 9.2 ng/mL at week 4 in 18
psychotic patients who had no relapses [106]. Serum olanzapine concentration drop varied from 2 to 4
weeks and with valproate concentration and is likely to be explained by valproate induction on olanzapine
metabolism by CYPs or UGT. These changes, although statistically significant, were small and
presumably not clinically significant. However, as the valproate and olanzapine combination is
increasingly used, further studies are necessary to elucidate the mechanisms (induction, competitive
inhibition and/or protein binding displacement), severity and duration of this DI and to understand
whether there are any circumstances (e.g., high or low olanzapine or valproate doses) in which this DI
may acquire clinical relevance [107].
2.1.6.4. Valproate on quetiapine. Valproate studies on quetiapine metabolism provided inconsistent
results. A 77% increase in quetiapine C/D, when compared to quetiapine monotherapy in 9 patients taking
valproate, led Aichorn et al. to propose a CYP3A4-inhibition of quetiapine metabolism by valproate
[108]. However no relevant changes in quetiapine metabolism were found in two TDM routine studies
[72, 73] and in a formal pharmacokinetic study in 34 psychotic patients taking 300 mg/day of quetiapine
and 1000 mg/day of divalproex [109].
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2.1.6.5. Valproate on risperidone. No major changes in risperidone moiety were found in: i) a
pharmacokinetic study comparing 23 patients on monotherapy versus 10 on valproate (1200-1500
mg/day) [77], ii) its extension to 3 patients on/off valproate [77], and iii) another pharmacokinetic study
of 22 bipolar patients taking valproate (1000 mg/day) in which half were randomized to placebo or
risperidone up to 4 mg/day [110]. This is consistent with the absence of an inhibitory effect of valproate
on CYP2D6 or CYP3A4, the major risperidone metabolic pathways.
2.2. Predicting metabolic DIs for new compounds
2.2.1. Other AEDs
The DI information for other SGAEDs is limited. Eslicarbazepine and rufinamide (as well as the
older felbamate) are mild CYP3A4-inducers. Rufinamide is also a possible UGT-inducer.
Eslicarbazepine, felbamate and rufinamide have limited potential to induce SGAP metabolism. As
CYP2C19 is not important in SGAP metabolism, the weak CYP2C19 inhibition by eslicarbazepine and
felbamate is not likely to be relevant. Stiripentol is a potent inhibitor of CYP2C19, CYP1A2, CYP2D6,
and CYP3A4 but is only used in Europe for the treatment of severe myoclonic epilepsy in infancy and is
not likely to be co-prescribed with SGAPs.
2.2.2. New SGAPs
2.2.2.1. Asenapine. UGT1A4 and CYP1A2 metabolize asenapine. Valproate (1000 mg/day for 9 days)
substantially reduced the formation of the N-glucuronide (AUC reduced 7.4-fold) and moderately reduced
that of N-desmethyl-asenapine (AUC reduced 30%) but did not affect asenapine AUC in an open-label,
randomized, 2-way crossover study in 24 healthy male volunteers receiving 5 mg of asenapine alone or a
low valproate dose. The study’s authors, who were from the asenapine-marketing company, concluded
that low-dose valproate, although almost completely inhibiting asenapine glucuronidation, did not affect
asenapine clearance [111]. Asenapine’s package insert indicates that: 1) 800 mg/day of carbamazepine for
15 days had small effects on asenapine AUC (16% decrease), and 2) no dosage adjustments are required.
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Independent studies using multiple dosing are required to verify that the valproate and carbamazepine DIs
with asenapine have no clinical relevance.
2.2.2.2. Iloperidone. Iloperidone is metabolized by CYP2D6 and CYP3A4 [112]. CYP3A4 inhibitors
have clinically relevant effects on iloperidone levels. There are no published studies of potent CYP3A4
inducers which are expected to relevantly increase iloperidone metabolism.
2.2.2.3. Lurasidone. Lurasidone is metabolized by CYP3A4 [113]. According to the US package insert,
rifampin, a potent CYP3A4-inducer, decreased lurasidone AUC 5-fold. There are no published studies of
potent CYP3A4 inducers which are expected to dramatically increase lurasidone metabolism. It is
possible that in high doses oxcarbazepine or topiramate may influence lurasidone levels.
2.3. Limited studies on pharmacodynamic DIs
This subsection classifies pharmacodynamic DIs as those increasing efficacy, increasing safety,
decreasing efficacy, and decreasing safety. The most important are included in Table 5.
2.3.1 Pharmacodynamic DIs increasing efficacy
Several SGAPs have been approved in the US for mania as adjuvant therapy to valproate (and
lithium), including aripiprazole, asenapine, quetiapine, risperidone and olanzapine. In the RCTs, tested
SGAPs were significantly more efficacious than adding placebo to valproate (or lithium). Thus, an
additive (or synergistic) effect (see subsection 1.4.3.) between valproate and SGAPs is expected in mania
(Table 5). In a review, Ketter described the response rate to valproate (and lithium) as increasing from
21% to 42% when adding SGAPs [114], which suggests additive rather than synergistic effects.
2.3.2. Pharmacodynamic DIs increasing safety
Topiramate and zonisamide can decrease weight (Figure 2 and Table 5). Topiramate has been
associated with reversing SGAP-induced weight gain in an open study [115].
2.3.2. Pharmacodynamic DIs decreasing efficacy
Figures 2-5 indicate that AEDs and SGAPs sometimes have opposite actions. All SGAPs, but
particularly clozapine and to a lesser extent olanzapine and quetiapine (Figure 5), have potential to
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decrease the seizure threshold and therefore contribute to seizures [53]. If a patient with epilepsy needs an
SGAP, the potential for increased seizures needs to be considered. This is easily managed by monitoring
AED treatment closely and considering increased AED doses, but in patients with not-well-controlled
seizures, adding an SGAP that lowers the seizure threshold may produce a clinically relevant
pharmacodynamic DI.
In epileptic patients, some AEDs (ethosuximide, levetiracetam, tiagabine, topiramate, vigabatrin
and zonisamide) have rarely been associated with psychosis (usually a transient paranoid psychosis;
Figure 3). As the pharmacodynamic mechanism is unknown, clinicians may want to remember this risk
when considering co-prescribing them with SGAPs in patients whose psychosis is not well-controlled. In
epileptic patients, some AEDs (particularly barbiturates, topiramate and vigabatrin, and less frequently
felbamate, levetiracetam, tiagabine, and zonisamide) have been associated with depression (Figure 3).
Clinicians may want to remember this risk when considering co-prescribing these AEDs with SGAPs in
patients with bipolar disorder or treatment-resistant depression since they have the potential to antagonize
the antidepressant SGAP properties. A Food and Drug Administration (FDA) meta-analysis of the
placebo RCTs suggests that patients taking AEDs have an increased risk of suicidal thoughts and
behaviors observed 1 week after taking the medication; the risk continues for at least 24 weeks which has
led to a warning in the package inserts of all anticonvulsants [116]. Recently, reviews questioned the FDA
warning in the prescription packages for all AEDs [117] and large pharmacoepidemiological studies
suggested contradictory findings for AEDs in general [118,119]. In our opinion, 1) the FDA decision to
include a warning about increased suicide risk in all antiepileptic prescribing information has increased
awareness, but oversimplified a complex matter; 2) the risk of completed suicide in persons with suicidal
ideation is probably low, while completed suicide risk increases 40-fold after a prior attempt [120]; and 3)
other factors such as medical and psychiatric illnesses can partially explain the increased suicide risk in
patients taking AEDs.
2.3.3. Pharmacodynamic DIs decreasing safety.
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There are multiple pharmacodynamic DIs that have potential to increase ADRs by additive or
synergistic effects. These DIs are likely to be clinically relevant but have not been systematically studied.
They can be divided into common, probably less common and rare, but potentially lethal, categories.
Three common pharmacodynamic DIs are sedation, weight gain and swallowing disturbances
(Table 5). A recent well-controlled 12-month study indicated that the valproate-olanzapine combination
was worse for metabolic syndrome than the valproate-risperidone combination [121]. Dysphagia is
particularly frequent in patients with intellectual disabilities or dementia. Although it has not been studied
additive or synergistic pharmacodynamic DI actions on swallowing disturbances are likely between AEDs
and SGAPs. Table 5 emphasizes two probably uncommon pharmacodynamic DIs, nausea/vomiting and
osteoporosis, which have never been studied, and includes three rare, but potentially lethal
pharmacodynamic DIs: pancreatitis, agranulocytosis and heat stroke. Carbamazepine and clozapine
should not be combined due to their risk for agranulocytosis. Valproate and other SGAPs besides
clozapine have occasionally been associated with neutropenias due to not well-understood mechanisms.
Rahman et al. have described neutropenia and leucopenia cases with the combination of valproate and
quetiapine [122].

3. Conclusion
This section and Table 5 provide a summary of the most important practical DI information for
clinicians.
3.1. Pharmacokinetic DIs and clinical implications
Carbamazepine, phenobarbital, phenytoin and primidone are potent inducers that are likely to have
clinically relevant effects on several SGAP levels (Table 5). Adding any of these inducers (in the absence
of other inducers) may be associated with a decrease in SGAP serum concentration that may be associated
with lack of efficacy. The discontinuation of these inducers (when other inducers are not prescribed) may
be associated with an increase in SGAP serum concentration that may be associated with ADRs. The best
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way to control for these DIs is by checking SGAP TDM. As SGAP TDM may not be available, Table 5
provides a best estimation of a correction factor (Figure 1) based on the limited available literature.
The pharmacokinetic DIs associated with valproate or the mild AED inducers eslicarbazepine,
felbamate, oxcarbazepine, rufinamide and topiramate (Table 5) are not likely to be clinically relevant in
most patients taking SGAPs, but it cannot be ruled out that in some unusual patients they may have
clinical relevance. In that sense, clinicians may need to be watchful when using high doses of
oxcarbazepine (≥ 1500 mg/day) [10] or topiramate (≥ 400 mg/day) [11], particularly with highly inducible
SGAPs such as quetiapine or lurasidone.
3.2. Pharmacodynamic DIs and clinical implications
As described in Section 2.3, the literature is very limited in the description of pharmacodynamic
DIs but in our experience these types of DIs are very relevant in clinical practice (Table 5). Two
pharmacodynamic DIs can be considered positive: i) the additive effects for mania and bipolar
maintenance when combining valproate and SGAPs and ii) the decrease in weight that may be associated
with combining topiramate or zonisamide with SGAPs.
In our experience with neurologists managing AED prescriptions and psychiatrists prescribing
SGAPs, these specialists rarely pay enough attention to the other’s prescriptions, which may lead to high
potential for pharmacodynamic DIs. Three additive DIs are common: increased sedation, weight gain and
swallowing disturbances. However, different AEDs and SGAPs have different risks for sedation or
weight gain (Table 5). As swallowing impairment is usually a neglected ADR in published studies, there
is no information on whether different AEDs or SGAPs have different risks for swallowing impairment.
From the probably uncommon pharmacodynamic DIs, Table 5 highlights the potential for increased risk
for osteoporosis and nausea for a few combinations of AEDs and SGAPs. Finally, Table 5 describes three
potentially lethal pharmacodynamic DIs: pancreatitis, agranulocytosis/leucopenia and heat stroke. These
ADRs are very rare and we are not sure that combinations of AEDs and SGAPs increase their risk but
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pharmacological mechanisms suggest that it is a possibility and clinicians need to remember that in order
to prevent or quickly diagnose these ADRs.

4. Expert opinion
We have excellent understanding of the clinical relevance of DIs associated with the inductive
properties of carbamazepine, phenytoin, phenobarbital and primidone and with the inhibitory properties of
valproate. Unfortunately, the DI studies with SGAPs are rather limited but adding or discontinuing
phenytoin, phenobarbital and primidone are likely to have clinically relevant effects on SGAP treatments.
Table 5 provides correction factors based on the limited available literature. These correction factors
were calculated using the available pharmacokinetic studies which summarize the data, assuming that the
average patient represents the population well; however, there is extensive pharmacokinetic variability
between patients, and TDM measurements should be advised for optimal titration of the dosage in each
individual. In spite of their limitations, these corrections factors are useful because: 1) many clinicians
have no access to antipsychotic TDM and, as a matter of fact, there is limited clinical data on some SGAP
TDM (amisulpride, aripiprazole, paliperidone, quetiapine, and ziprasidone) and very limited data on three
compounds (asenapine, iloperidone and lurasidone); and 2) in our experience, having the correction factor
helps clinicians to make decisions. With a correction factor of 5, quetiapine and lurasidone are poor
SGAP choices for patients taking powerful AED inducers. The correction factors may not fully account
for all of the possible risks of treatment because of the limited studies available; thus, there will be a need
to periodically update these correction factors as new knowledge becomes available.
Eslicarbazepine, felbamate, and rufinamide are thought to be mild inducers but there are no studies
on SGAPs to verify their limited clinical relevance. A serious limitation of the SGAP DI literature is the
lack of studies in clinical samples with high doses of oxcarbazepine (≥ 1500 mg/day) or topiramate (≥ 400
mg/day) that would establish whether or not they induce in a clinically relevant way SGAPs dependent on
CYP3A4 (aripiprazole, lurasidone, quetiapine and risperidone) or UGTs (asenapine and olanzapine) for
their metabolism. As Table 5 indicates, it is very likely that AED inducers have major effects in
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lurasidone metabolism since rifampin, another potent and widespread inducer, increased lurasidone
metabolism by a factor of 5. Clinicians may need to be very careful with iloperidone and particularly
asenapine. Asenapine metabolism by UGT1A4 and CYP1A2 suggests asenapine has major potential for
being induced by carbamazepine, phenytoin, phenobarbital and primidone. There is no way of providing a
correction factor since we are unaware of any other drug with similar metabolism to asenapine. On the
other hand, one would like to see asenapine DI studies with repeated dosing in clinical samples, to be
reassured that valproate effects on asenapine metabolism can be ignored by clinicians. We suspect that the
valproate effects are small in most patients taking SGAPs but we keep surprising ourselves by finding
unexpected valproate DIs, particularly as a possible inducer of: i) clozapine in smokers [99], or ii)
olanzapine [106], which may be relevant in extreme conditions (valproate levels ≥ 80 μg/ml and
olanzapine doses ≤ 10 mg/d) [107]. Paliperidone studies with strong inducers published by independent
investigators are needed.
It is not easy to conduct DI studies using clinically relevant doses. Pharmaceutical companies tend
to invest in simple pharmacokinetic DI studies in volunteers frequently using single dosing to get
approval for the marketing of their drugs, but this type of pharmacokinetic study rarely reflects clinical
practice. DI information on package inserts is usually not designed to provide easy information to help
clinicians to correct pharmacokinetic DIs with dose changes. The pharmacokinetic science on AEDSGAP combinations may be in its adolescence and needing maturation, while pharmacodynamic DI
science appears to be in its infancy. None of the studies combining AEDs with mood stabilizers and
SGAPs explore whether the combinations are additive or synergistic. Recent meta-analyses determined
the effects of different monotherapies in mania, bipolar depression or maintenance but there is no
published meta-analysis of the combinations, although most patients are treated with combinations. There
are almost no well-controlled studies of AEDs or SGAPs in patients with aggressive behaviors or in
adults with epilepsy and intellectual disabilities, although clinicians use AED-SGAP combinations
frequently in them.
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It would be naïve to simply conclude that more studies of AED-SGAP DIs are needed. They are
obviously needed, but the lack of funding for clinical research is a major limitation. To progress in this
area, collaboration from all interested parties is needed, including: i) drug agencies and pharmaceutical
companies; ii) clinicians using AED-SGAP combinations; iii) researchers with expertise in a) metaanalyses, b) pharmacoepidemiology, and c) DI pharmacology; and iv) grant agencies.
Drug agencies should be more insistent upon rapid approval of new SGAPs in bipolar disorder
and require: i) thorough studies of the pharmacodynamic and pharmacokinetic DIs with carbamazepine,
lamotrigine, lithium and valproate; and ii) clear package insert guidelines of how to better avoid or correct
for pharmacodynamic and pharmacokinetic DIs. Carbamazepine is an anti-manic agent and probably a
mood stabilizer, but it took too many years to get FDA approval for a bipolar disorder indication due to
lack of interest from the pharmaceutical companies. Carbamazepine use is limited by its potential for
toxicity, teratogenicity and DIs. If oxcarbazepine is judged to be as effective as carbamazepine in bipolar
disorder, carbamazepine should replace oxcarbazepine. The FDA may need to think “out of the box” and
look for new ways to encourage pharmaceutical companies possibly interested in marketing
oxcarbazepine in bipolar disorder by providing special “deals”, assuming the companies seriously want to
study DI issues, including the possible impact of high oxcarbazepine doses. Similarly, as several AEDs
with chemical formulations similar to already marketed AEDs are being studied for approval for epilepsy
(e.g., DP-valproic acid or phosphatidylcholine estric conjugate of valproic acid) the FDA and other
agencies need to think “out of the box” about encouraging and simplifying the process of approval of
these new AEDs for bipolar disorder.
Clinicians frequently co-prescribe AEDs and SGAPs. Neurologists may prescribe SGAPs in their
patients with epilepsy or other non-epileptic conditions (pain or migraine) that need treatment for
psychosis, bipolar disorder or other SGAP off-label conditions. Psychiatrists may prescribe AEDs as
mood stabilizers or for off-label indications in patients taking SAGPs. Thousands of US patients take
these combinations. There is great need of naturalistic studies describing possible additive or synergistic
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efficacy and, more importantly, the long-term safety of these combinations. Are early sedation or early
nausea and vomiting more frequent in some of these combinations that in the various monotherapies? Is
swallowing impairment or osteoporosis a long-term issue in vulnerable patients taking some of these
combinations for years?
Researchers with expertise in meta-analysis may need to develop better methods to study: i) safety
of AED-SGAP combinations by comparing ADRs in available SGAP RCTs in monotherapy in
schizophrenia versus those on adjuvant therapy in bipolar disorder, and ii) how bipolar disorder studies
can better compare efficacy of individual drugs versus drug combinations. Researchers with expertise in
pharmacoepidemiology need to explore whether rare ADRs such as risk of pancreatitis,
agranulocytosis/leucopenia and heat stroke may be more frequently associated with AED-SGAP
combinations than with individual drugs. Researchers with expertise in in vitro DI studies or in vivo
clinical studies using isotopes to explore drug clearance need to better study the SGAP metabolic
pathways and how they change when inhibitors and inducers are added, particularly in the complicated
conditions used in clinical practices such as adding both an inducer and an inhibitor to an SGAP (e.g.,
adding carbamazepine and fluoxetine to risperidone).
Grant and health agencies need to remember that pragmatic clinical trials are key in treating
complex disorders such as epilepsy, schizophrenia and bipolar disorder, where polytherapy is the norm.
Pharmaceutical RCTs do not substitute for long-term pragmatic trials that may better inform clinicians of
the effectiveness of the various types of mono- and polytherapy frequently used in the real world of
clinical practice. Pragmatic trials need to pay better attention to DI.
Progress in the next few years, if this research agenda is followed, should also be accompanied by
a better continuous medical education on DIs and improvements in neuropsychopharmacology textbooks,
so that clinicians begin to pay more attention to pharmacodynamic and pharmacokinetic DIs associated
with the frequent co-prescription of AEDs and SGAPs. Well-educated clinicians will help move the
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research agenda by publishing DI case reports of unusual combinations and asking for more DI studies
from pharmaceutical companies and researchers.
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OTHER PHARMACOKINETIC ISSUES
P-GLYCOPROTEIN (P-gp)
1) P-gp plays a central role in the absorption, distribution and excretion of a wide variety of drugs.
2) P-gp is a multidrug efflux transporter, encoded by the MDR1 gene (or ABCB1), highly expressed in
the intestine, brain, liver and kidney.
3) It acts as a natural defense mechanism against several drugs by limiting their absorption from the gut
and penetration into the brain, and promoting their elimination in the bile and urine.
4) Like metabolizing enzymes, P-gp activity can be inhibited or induced by other agents, altering the
concentration of substrate drug in blood and brain. In particular, some antiepileptic drugs (AED)
pharmacokinetic drug-drug interactions (DIs) currently attributed to enzyme induction may, in fact, be
due to overexpression of such transporters resulting in the affected drug having limited gastrointestinal
absorption or reduced penetration to the brain, or enhanced elimination in the bile and urine.
5) Second-generation antipsychotics (SGAPs) have been reported to show various degrees of inhibitory
effects on P-gp activity.
6) In summary, P-gp activity is probably relevant in explaining AED and SGAP DIs but our current
knowledge is too limited to determine P-gp’s importance.
PROTEIN BINDING
1) Theoretically, protein binding displacement interactions may occur between AED and SGAPs.
2) Competition between two drugs for binding sites on plasma proteins may elevate levels of the
displaced drug’s free fraction in plasma or tissue, thereby potentially increasing its pharmacological
effects.
3) However, in most circumstances this type of DI is not clinically relevant since the displaced drug is
diluted into a large volume of distribution or is rapidly cleared, and the unbound, pharmacologically
active concentration remains almost unchanged.
4) In quantitative terms, displacement interactions may only be important for drugs that are highly bound
to plasma proteins (>90%). A number of SGAPs are extensively bound to plasma proteins (Table 2),
while among AEDs only phenytoin, valproate and tiagabine belong to this category (Table 1).
5) Clinically relevant DIs due to increased free concentrations have occasionally been described for
phenytoin and valproate [7], but the other AEDs or anti-inflammatory drugs usually cause increased
valproate or phenytoin free concentrations.
6) No clear cases of SGAPs increasing free phenytoin or valproate concentrations have been published in
the literature.
Figure 1. Other pharmacokinetic issues.
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PHARMACODYNAMICS FOR ANTIEPILEPTIC EFFICACY
ANTIEPILEPTIC ACTIVITY
↓ Activity of voltage-dependent sodium channels
carbamazepine,eslicarbazepine,felbamate,lacosamide,lamotrigine,oxcarbazepine,phenytoin,rufinamide,topiramate,zonisamide

↓ Activity of voltage-dependent calcium channels
ethosuximide, gabapentin, levetiracetam, lamotrigine, pregabalin, topiramate, zonisamide

↑ GABA neurotransmission

felbamate, levetiracetam, phenobarbital, primidone, stiripentol, tiagabine, topiramate, vigabatrin, valproate1

↓ Glutamatergic neurotransmission
felbamate, topiramate, zonisamide

Other

levetiracetam,2 retigabine,3

MOOD STABILIZER ACTIVITY4
At intracellular signaling system (inositol signaling)
5

carbamazepine, valproate

Not well understood
Lamotrigine

ANXIOLYTIC ACTIVITY
↑ GABA neurotransmission
pregabalin6

FOR PAIN7
↓ Activity of voltage-dependent sodium or calcium channels
carbamazepine, gabapentin, oxcarbazepine, pregabalin

FOR MIGRAINE PROPHYLAXIS8
↓ Activity of voltage-dependent sodium and calcium channels
topiramate

↑ GABA neurotransmission
valproate,1 topiramate

↓ Glutamatergic neurotransmission
Topiramate

WEGHT LOSS (not approved treatment)9
Probably by inhibition of carbonic anhydrase
topiramate, zonisamide

Figure 2. Pharmacodynamics for antiepileptic efficacy.
ADRs: adverse drug reactions; AED: antiepileptic drug; RTC: randomized clinical trial.
1
There is general agreement that valproate acts mainly by increasing GABAergic neurotransmission but a
more precise description might be that valproate has complex actions, since valproate may act at the
voltage-dependent sodium and calcium channels [13].
2
Levetiracetam has complex actions including one that appears specific to this compound: binding to
synaptic vesicle protein 2A interfering with the recycling of synaptic vesicles and the release of a range of
neurotransmitters [14].
3
Retigabine appears to open potassium channels [14].
4
AEDs approved in the US for bipolar disorder include: i) valproate for mania; ii) carbamazepine for the
treatment of acute manic and mixed episodes of bipolar disorder; and iii) lamotrigine for prophylaxis,
particularly of depressive phases [15]. Treatment guidelines also consider: 1) valproate monotherapy or
adjunctive for bipolar depression or prophylaxis, ii) carbamazepine monotherapy or adjunctive for
prophylaxis, and iii) lamotrigine monotherapy or adjunctive for bipolar depression [15]. Gabapentin,
lamotrigine and topiramate mania RCTs were negative [15]. Oxcarbazepine bipolar disorder RCTs appear
promising. There are no published RCTs for eslicarbazepine, levetiracetam or zonisamide.

5
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Valproate is a histone deacetylase inhibitor. It is not known whether this action contributes to its mood
stabilizing properties or not [16].
6
Pregabalin is approved for generalized anxiety disorder in Europe but not in the US. Other AEDs may
have antianxiety properties [17].
7
In the US approved drugs include: i) carbamazepine for trigeminal neuralgia, ii) gabapentin for
postherpetic neuralgia, and iii) pregabalin for postherpetic neuralgia and diabetic neuropathic pain.
Lacosamide is being studied in RCTs for diabetic neuropathic pain. Oxcarbazepine is usually considered
an alternative for trigeminal neuralgia when patients cannot tolerate carbamazepine. Johannessen
Landmark considers other AEDs, including levetiracetam, lamotrigine and phenytoin, as acceptable
treatments for neuropathic pain [3].
8
In the US, the only AEDs approved for migraine prophylaxis are topiramate and valproate.
9
Topiramate and zonisamide treatments are frequently associated with weight loss but are not approved
for that indication in the US. These two drugs were associated with too many ADRs in obesity RCTs [18,
19].
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PHARMACODYNAMICS FOR ANTIEPILEPTIC SAFETY
SEDATION

FGAED and topiramate >2 other SGAEDs1 >2 felbamate, lacosamide, lamotrigine, tiagabine

Possibly the same mechanism that explains antiepileptic efficacy
COGNITIVE IMPAIRMENT
Definitively in FGAEDs and probably in SGAEDs3

Possibly the same mechanism that explains antiepileptic efficacy4
BALANCE DISTURBANCES
Most AEDS5

Unknown/possibly the same mechanisms that explain antiepileptic efficacy
NAUSEA AND VOMITING
carbamazepine,eslicarbazepine,felbamate,lacosamide,lamotrigine,oxcarbazepine,phenytoin,rufinamide,topiramate,zonisamide

Possibly ↓ activity of voltage-dependent sodium channels6
ethosuximide, tiagabine, valproate

Unknown
DEPRESSION

phenobarbital, primidone, topiramate, vigabatrin >2 zonisamide >2 felbamate, levetiracetam, tiagabine7

Possibly ↑ GABA neurotransmission
PSYCHOSIS (rare)

ethosuximide, levetiracetam, lamotrigine, topiramate, tiagabine, vigabatrin, zonisamide8

Unknown mechanisms
AGGRESSIVE BEHAVIOR (rare)

gabapentin, levetiracetam, lamotrigine, phenobarbital, topiramate, vigabatrin, zonisamide9

Unknown mechanisms
OSTEOPOROSIS (relatively uncommon)

carbamazepine, phenobarbital, phenytoin, primidone10

Induction of Vitamin D metabolism
THYROID DISTURBANCES (relatively uncommon)
carbamazepine, phenytoin11

Probably induction of thyroid hormone metabolism
IDIOSYNCRATIC (very rare: 1-10/10,000-100,000)
Stevens–Johnson syndrome/toxic epidermal necrolysis

carbamazepine, ethosuximide, felbamate, lamotrigine, phenobarbital, phenytoin, primidone12

Agranulocytosis and/or aplastic anemia13

carbamazepine, ethosuximide, felbamate, phenobarbital, primidone, valproate

Hepatitis/liver failure
carbamazepine, felbamate, phenytoin, valproate

Immunological and/or toxic mechanisms
RISK FOR HEAT STROKE (very rare)14
topiramate, zonisamide

Inhibition of carbonic anhydrase causes sweating inhibition
PANCREATITIS (rare)15
valproate

Mechanism is poorly understood
Figure 3. Pharmacodynamics for antiepileptic safety.
ADR: adverse drug reaction; AED: antiepileptic drug; FGAED: first-generation antiepileptic drug;
SGAED: second-generation antiepileptic drug.
1
All FGAEDs are definitively associated with sedation [20]. A meta-analysis found that most SGAEDs
(gabapentin, levetiracetam, pregabalin, topiramate and zonisamide) were associated with somnolence
when compared with placebo [20]. Other SGAEDs including oxcarbazepine, vigabatrin [20],
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eslicarbazepine, retigabine, and rufinamide [21] also are probably associated with sedation. Felbamate,
lacosamide, lamotrigine, and tiagabine appear to be associated with low sedation risk [20, 22].
2
Drugs preceding ">" will produce this ADR more frequently than drugs following ">".
3
FGAEDs are associated with cognitive impairment in studies using neuropsychological testing. There
are few neuropsychological studies on SGAEDs. Different authors agree that phenobarbital has the worst
cognitive profile among FGAEDs, and topiramate among SGAEDs, but disagree on the relative
impairment associated with specific compounds and how topiramate compares with FGAEDs [23, 24].
Vigabatrin can be associated with visual defect fields.
4
[24]
5
FGAEDs (except for ethosuximide) are definitively associated with ataxia and other balance disturbances
[20]. A meta-analysis indicated most SGAEDs (lamotrigine, oxcarbazepine, pregabalin, tiagabine,
topiramate and zonisamide) are associated with balance disturbances while gabapentin and levetiracetam
may not be [25]. Other AEDs including felbamate, vigabatrin [20], eslicarbazepine, lacosamide,
retigabine, and rufinamide [25] are probably associated with balance disturbances.
6
Beydoun et al. proposed that nausea and vomiting may be explained by decreased activity of voltagedependent sodium channels [26]. Review articles focused on AED pharmacodynamics do not comment on
possible mechanisms that may explain AED-induced nausea and vomiting.
7
Different reviews provide different frequencies of each AED-induced depression. A comprehensive
review described frequencies >10% for phenobarbital, primidone, topiramate and vigabatrin; 7% for
zonisamide in high doses; ≤4% for felbamate, levetiracetam and tiagabine; and <1% for the rest of the
studied AEDs. On the other hand, carbamazepine, lamotrigine, oxcarbazepine and valproate may have
antidepressant properties in patients with epilepsy [27].
8
It is difficult to assess when psychosis is really an AED ADR rather than a manifestation of the
underlying or associated illnesses. AEDs associated with psychosis include levetiracetam, lamotrigine,
topiramate, tiagabine, vigabatrin [28], ethosuximide [29] and zonisamide [30]. Studies using lamotrigine
and topiramate in bipolar disorder do not describe increased psychotic symptoms.
9
It is difficult to assess when aggressive behavior is really an AED ADR rather than an underlying or
associated illness. AEDs associated with irritability or aggression are gabapentin, levetiracetam,
lamotrigine, phenobarbital, topiramate, vigabatrin [31] and zonisamide [30].
10
Oxcarbazepine may also be associated with osteoporosis risk. Valproate also appears to be associated
with osteoporosis but the mechanism is not well understood.
11
Oxcarbazepine may be associated with mild thyroid disturbances.
12
Other AEDs less clearly associated with Stevens–Johnson syndrome/toxic epidermal necrolysis are
oxcarbazepine, valproate and zonisamide.
13
Valproate is frequently associated with thrombocytopenia and more rarely, with neutropenia. Valproateinduced thrombocytopenia appears to be dose-related and explained by direct toxic mechanism rather than
by immunological mechanism.
14
The literature describes most cases of heat stroke associated with topiramate [32] or zonisamide [33] as
occurring in children but adult cases during a heat wave have been described [34].
15
The literature describes valproate-induced pancreatitis as very rare. A comprehensive review in
Germany indicated that milder cases are much more common than the literature suggests [35]. In a review
of all 5 years of data from a facility for 322 adults with intellectual disabilities, the frequency of
pancreatitis in patients taking valproate was not rare; it was 7% (5/72 patients) [36]. The first author has
similar experience that pancreatitis is not rare in these facilities.
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PHARMACODYNAMICS FOR SGAP EFFICACY
BLOCKADE OF D2 RECEPTORS AT BASAL GANGLIA AND CORTEX1
Explains antipsychotic efficacy in schizophrenia
All SGAPs are approved2

Explains antipsychotic efficacy in other psychoses
None are approved in the US3

Possibly explains anti-manic properties4

aripiprazole, olanzapine, quetiapine, risperidone and ziprasidone are approved in the US as montherapy5

Possibly explains postulated mood-stabilizing properties (maintenance in bipolar disorder)
aripiprazole and olanzapine are approved in the US as monotherapy6

Possibly explains anti-irritability action in autism
aripiprazole and risperidone are approved in the US

Possibly explains postulated anti-OCD properties when added to serotonergic
antidepressants7
None are approved in the US but reasonable data exist on risperidone7,8

DEPRESSION
Treatment of bipolar depression
quetiapine is approved in the US

Adjunctive therapy of treatment-resistant depression
aripiprazole, quetiapine, olanzapine are approved in the US9

Mechanism of action is unknown10
Figure 4. Pharmacodynamics of efficacy for second-generation antipsychotics
5-HT: serotonin receptor; AP: antipsychotic; D: dopamine receptor; RCT: randomized clinical trial;
SGAP: second-generation antipsychotic.
1
All APs are D2 antagonists except for aripiprazole which is a partial agonist (some authors have proposed
that occasionally aripiprazole can be associated with worsening of psychosis). Brain imaging studies
indicate that antipsychotic efficacy may be associated with D2 blockade at the basal ganglia and cortex.
2
Amisulpride is approved in Europe but has not been studied for approval in the US.
3
No SGAP is approved for psychosis (or behaviors) in dementing illness. Paliperidone is approved for
schizoaffective disorder in the US.
4
[37]
5
Aripiprazole, asenapine, quetiapine, risperidone, and olanzapine have been approved for adjunctive
therapy with lithium or valproate. Other SGAPs have not been studied in RCTs.
6
Quetiapine has been approved for adjunctive therapy with lithium or valproate.
7
[6]
8
[6]
9
Olanzapine is approved in combination with fluoxetine. Risperidone had some positive results in RCTs
[38].
10
The mechanisms proposed in bipolar depression include: i) a high ratio between 5-HT2A/D2 receptors
[37], and ii) a possible role for 5-HT2A or α2 blockade [39]. Common mechanisms proposed for adjunctive
treatment in major depressive disorder include 5-HT2A blockade that may be shared by approved SGAPs
[38]. Specific mechanism include: i) 5-HT1A partial agonism only for aripiprazole [38]; and 5-HT2C
antagonist and inhibition of noradrenaline transporter by norquetiapine, the main active metabolite of
quetiapine [40]. Ziprasidone at clinical dose blocks reuptake of serotonin, noradrenaline and dopamine
[41], which may suggest potential for antidepressant properties but the only published ziprasidone trial in
bipolar depression indicated this compound had no more efficacy than placebo [42].
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PHARMACODYNAMICS FOR SGAP SAFETY
BRAIN
EXTRAPYRAMIDAL SYMPTOMS

amisulpride,paliperidone,risperidone>1asenapine,iloperidone,lurasidone,olanzapine,ziprasidone>1quetiapine>1clozapine2

Blockade of D2 receptors at nigrostriatal system2
HYPERPROLACTINEMIA

amisulpride,paliperidone,risperidone>1asenapine,iloperidone,lurasidone,olanzapine,ziprasidone>1quetiapine,clozapine>1
aripiprazole3

Blockade of D2 receptors at tubero-infundibular system4
WEIGHT GAIN

clozapine, olanzapine>1 asenapine, paliperidone, quetiapine, risperidone >
1
amisulpride, aripiprazole, iloperidone, lurasidone, ziprasidone2

Blockade of H1 (and others including 5-HT2C and M) receptors5
SEDATION
clozapine >1asenapine, olanzapine >1 quetiapine >1 other SGAPs6

Blockade of brain H1 receptors7
MEMORY IMPAIRMENT
Associated with high blockade of brain muscarinic receptors in schizophrenia patients6
Possible with clozapine 8

↓ SEIZURE THRESHOLD

clozapine >1 olanzapine, quetiapine >1 other SGAPs 9

D2, H1 and α1 receptor blockade, actions at neurosteroids or by pharmacological kindling10
PERIPHERAL (with/without brain component)
HYPERGLYCEMIA/HYPERLIPIDEMIA
Secondary to weight gain (see above)
Direct effects on glucose/lipid metabolism
clozapine, olanzapine, quetiapine 11

SEXUAL SIDE EFFECTS

clozapine, risperidone, olanzapine >1 aripiprazole, quetiapine, ziprasidone12

Hyperprolactinemia (see above) and blockade of peripheral α, M and H receptors13
ORTHOSTATIC HYPOTENSION
clozapine, iloperidone, risperidone, quetiapine, ziprasidone14

Blockade of peripheral α1 receptors
ANTICHOLINERGIC SYMPTOMS
(Tachycardia, constipation, dry mouth, urinary retention, or blurred vision)
15

clozapine >1 olanzapine >1 quetiapine

Blockade of peripheral muscarinic receptors
NAUSEA
aripiprazole, lurasidone, ziprasidone

Unknown16
PROLONGATION OF QTC

iloperidone, ziprasidone >1 amisulpride, asenapine, clozapine, lurasidone, quetiapine, risperidone, olanzapine >1
aripiprazole17

Blockade of heart potassium repolarizing channels
AGRANULOCYTOSIS
clozapine (<1%)

Probably immunological
NEUTROPENIA (very rare)
Possibly ALL

Unknown
RISK FOR HEAT STROKE (very rare)
Most published cases also involve FGAPs18

Dopaminergic blockade interferes with temperature regulation
Muscarinic blockade from antiparkinsonian or from AP (see anticholinergic) inhibits sweating

Figure 5. Pharmacodynamics of safety for second-generation antipsychotics
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5-HT: serotonin receptor; ADR: adverse drug reaction; AP: antipsychotic; D: dopamine receptor; FGAP:
first-generation antipsychotic; H: histamine receptor; M: muscarinic receptor; SGAP: second-generation
antipsychotic.
1
Drugs preceding ">" will produce this ADR more frequently than drugs following ">".
2
Data from a comprehensive review [43] supplemented with data on asenapine [44], iloperidone [45] and
lurasidone [46].
3
Data from a comprehensive review [43] supplemented with data on asenapine [44], iloperidone [47] and
lurasidone [46].
4
All APs are D2 antagonists except for aripiprazole, a partial agonist. The lower propensity of SGAPs
other than aripiprazole to cause extrapyramidal symptoms is explained by two theories: i) a high ratio
between 5-HT2A/D2 receptors, and ii) low affinity and fast dissociation from D2 (only clozapine and
quetiapine will be “atypical” since they are displaced by endogenous dopamine) [48].
5
Studies relating weight gain within different APs and receptor affinity indicate that H1 affinity is the best
predictor of weight gain. Some animal studies indicate that H1 blockade of other receptors (particularly 5HT2C and muscarinic) may be needed to produce hyperphagia in animal studies [48].
6
Data from a comprehensive review [49] supplemented with data on asenapine [44] and iloperidone [45].
7
H1 antagonism is probably the major contributing mechanism to sedation but other receptor blockade
may also contribute. Aripiprazole and ziprasidone have also been associated with early insomnia and
activation [50]. It is unknown whether these compounds’ pharmacodynamic differences or individual
susceptibility explain this activation.
8
Blockade of M1 and M2 receptors has been associated with impaired learning and memory in animal
studies [51]. It is difficult to detect cognitive impairment in the context of schizophrenia but high
antimuscarinic activity was associated with worse memory functioning in an AP meta-analysis.
Clozapine had a worse profile than risperidone and olanzapine [52]. Clozapine has definitively high
antimuscarinic activity. Olanzapine and high doses of quetiapine may also be associated with clinically
relevant antimuscarinic activity [52]. Thus, olanzapine and high doses of quetiapine may occasionally be
associated with memory impairment.
9
A comprehensive review [53] provided no comparative data on amisulpride, asenapine, iloperidone, or
lurasidone.
10
[54].
11
Other SGAPs may not have direct effects on glucose or lipid metabolism, but this has not been
completely established.
12
A meta-analysis provided no comparative data on amisulrpide, asenapine, iloperidone, or lurasidone
[55].
13
[55]. Priapism is rare but is the most severe sexual ADR and is probably explained by α1 (and possible
α2) receptor blockade [48].
14
Clozapine, iloperidone, risperidone, quetiapine, and ziprasidone need dose titration to avoid orthostatic
hypotension. Orthostatic changes are not seen after intramuscular injections of ziprasidone, so ziprasidone
probably has low risk of orthostatic hypotension. Other SGAPs with lower risk for orthostatic
hypotension are olanzapine (particularly in intramuscular preparation) and asenapine.
15
Clozapine causes hypersalivation. It is believed that clozapine may be a partial agonist at M1 and M3
receptors. Norclozapine, clozapine’s main metabolite, is definitively an allosteric agonist of M1 [51].
16
Antipsychotics, because of their dopaminergic blockade, are considered anti-emetic drugs, so it is not
known what mechanism explains the association of these three drugs with nausea in the first one or two
weeks of treatment. Other SGAPs may also occasionally be associated with nausea.
17
Data from a comprehensive review [43] supplemented with data on amisulpride [56], asenapine [44],
iloperidone [57] and lurasidone [58].
18
Most published cases including SGAPs also had FGAPs co-prescribed [59].
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Table 1. Pharmacokinetic parameters of antiepileptics.
Bioavail
Protein
Half- Most
-ability
binding
life (h) important
(%)
(%)
way of
elimination1
FIRST GENERATION
75-85
75
5-26
CYP3A42
Carbamazepine
Ethosuximide
Phenytoin

90-100
90

<10
90

25-70
7-80

CYP3A42
CYP2C92

Phenobarbital

>95

45-60

70-130

CYP2C92

Primidone

>90

10

5-20

CYP2C92

Valproate

>90

70-95

8-16

Several
UGTs

30
20-25
0
<15
55
<10
40

13-20
11-25
5-9
12-16
25
6-8
7-12

UGTs3
CYP3A42
Renal
CYP2C192
UGT1A42
Renal
Renal
Renal
Acetylation
Carboxylesterases

SECOND GENERATION
Eslicarbazepine
100
90
Felbamate
<65
Gabapentin
Lacosamide
100
>95
Lamotrigine
100
Levetiracetam
Oxcarbazepine
100
Pregabalin
Retigabine
Rufinamide

>90
60
85

0
80
30

5-7
8-10
8-12

Stiripentol

>70

99

4.5-13

Tiagabine
Topiramate
Vigabatrin
Zonisamide

100
100
>50
100

96
13-17
0
50

5-9
10-30
4-7
50-70

CYP3A42
Renal
Renal
CYP3A42

Other ways of elimination

Active metabolites

Non-linear kinetics

CYP2C8, CYP1A2, UGT2B7

Carbamazepine
epoxide7

Non-linear until
induction is stable

CYP2E1, renal
CYP2C19 (less important:
CYP2C18, CYP3A4)
CYP2C19, CYP2E1,
N-glucosidation, renal
Renal, CYP2C19, CYP2E1,
N-glucosidation,
-oxidation, CYP 2C9 (other
CYPs are minor)
Renal
Renal, CYP2E1, UGTs

Non-linear6

Phenobarbital

S-licarbazepine
Non-linear6

Renal
Esterase hydrolysis in blood
UGTs
UGTs
CYP1A2, CYP2C19, CYP3A4,
UGTs4
CYP
N-acetylation transferase, renal

Non-linear until
induction is stable
Non-linear until
induction is stable
Non-linear for total
concentration6

MHD (monohydroxy
derivate) 5
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CYP: cytochrome P450; UGT: uridine diphosphate glucuronosyl transferase
1
This refers to normal metabolism. Lack of polymorphic enzymes, as well as major inhibition or induction, can change the major way of eliminating the drug
from the body. In some CYPs (e.g., CYP2C19) some patients do not have active enzymes; they are called poor metabolizers (PMs). Others may have too much
enzyme; they are called ultrarapid metabolizers (UMs). If a drug is metabolized by a CYP associated with PMs or UMs, these subjects metabolize the drug in a
different way than average subjects. Adding a potent inhibitor that completely inhibits an enzyme causes a PM “phenocopy” as long the inhibitor effects are
present; adding an inducer causes a UM phenocopy as long the inducer effects are present.
2
Any substrate competes with others for the corresponding enzyme and inhibits it; the potency of the inhibition is influenced by substrate affinity and dose. In
most clinical situations competitive inhibition is probably irrelevant. In unusual polypharmacy situations, adding a competitive inhibitor (such as AEDs, which
are not normally considered inhibitors) in a patient taking a drug with a narrow therapeutic window may affect another drug’s drug metabolism due to inhibitor
accumulation past the tipping point.
3
Eslicarbazepine is a pro-drug that is activated by hepatic esterases to S-licarbazepine. S-licarbazepine is eliminated by UGTs and by the kidney (unchanged).
4
There are four metabolic pathways. No specific enzyme can be considered as the most important enzyme.
5
MHD is also called licarbazepine. Oxcarbazepine is a pro-drug and is activated by a cytosolic arylketone reductase that converts it to MHD, the active drug.
6
Metabolic saturation explains phenytoin non-linear kinetics. Protein binding saturation explains valproate non-linear kinetics for total serum concentrations.
Absorption saturation explains gabapentin and rufinamide nonlinear kinetics.
7
Carbamazepine epoxide is metabolized by an epoxide hydroxylase.
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Table 2. Pharmacokinetic parameters of second-generation antipsychotics.
Bioavailability
Protein
Half-life Most important way of
Other ways of elimination
Active metabolites
elimination1
(%)
binding (%)
(h)
43-48
17
12
Renal
Biliary
Amisulpride
2
CYP3A4
Dehydro-aripiprazole
87
99
48-68
CYP2D6
Aripiprazole
3
2
95
1-2
UGT 1A4
CYP1A2, CYP2D6, CYP3A4
35
Asenapine
CYP2C19, CYP3A4, CYP2D6 Norclozapine5
12-81
95
6-33
CYP1A22
Clozapine
CYP3A4, CYP1A2, CYP2E1 P88,6 P95
96
93
20-24
CYP2D62
Iloperidone
4
2
99
18
CYP3A4
ID-14823
9-19
Lurasidone
CYP2D6, UGT1A4, FMO
60-80
93
20-70
CYP1A22
Olanzapine
28
30
24
Renal
UGT, CYP2D6, CYP3A4
Paliperidone
CYP2D6
Norquetiapine
NA
83
5-8
CYP3A42
Quetiapine
CYP3A4, renal
9-hydroxy-risperidone
68
90
3-24
CYP2D62
Risperidone
99
4-10
Aldehyde oxidase
CYP3A4
604
Ziprasidone
CYP: cytochrome P450; NA: not available; UGT: uridine diphosphate glucuronosyl transferase
1
This refers to normal metabolism. Lack of polymorphic enzyme, as well as major inhibition or induction, can change the major way of eliminating the drug from
the body. In some CYPs (e.g., CYP2D6 and CYP2C19) some patients do not have active enzymes, they are called poor metabolizers (PMs). Others may have too
much enzyme; they are called ultrarapid metabolizers (UMs). If a drug is metabolized by a CYP associated with PMs or UMs, these subjects metabolize the drug
in a different way than average subjects. Adding a potent inhibitor that completely inhibits an enzyme causes a PM “phenocopy” as long the inhibitor effects are
present; adding an inducer causes a UM phenocopy as long the inducer effects are present. When patients are taking major inducers (carbamazepine,
phenobarbital, phenytoin or primidone), CYP3A4 may became the most important enzyme eliminating aripiprazole or risperidone.
2
Any substrate competes with others for the corresponding enzyme and inhibits it; the potency of the inhibition is influenced by substrate affinity and dose. In
most clinical situations competitive inhibition is probably irrelevant. In unusual polypharmacy situations, adding a competitive inhibitor (such as SGAPs which
are not normally considered inhibitors) in a patient taking a drug with a narrow therapeutic window may affect another drug’s drug metabolism due to inhibitor
accumulation past the tipping point.
3
Asenapine is administered sublingually; drinking or eating < 10 minutes after administration may decrease absorption.
4
Decreased absorption when not administered with food.
5
Norclozapine does not appear to have antipsychotic efficacy but it may contribute to anticholinergic effects and hypersalivation.
6
It does not cross the blood-brain barrier. It may contribute to peripheral adverse drug reactions.
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Table 3. Effects of antiepileptic drugs on the most common drug-metabolizing enzyme systems.
Antiepileptic
Induction
First-Generation Antiepileptics
Carbamazepine
Yes

Ethosuximide
Phenobarbital,
Primidone

Phenytoin

Valproic Acid

None2
Yes

Yes

Enzymes

Inhibition

Enzymes

CYP1A2, CYP2A6,
CYP2B6, CYP2C9,
CYP2C19, CYP3A4,
UGT1A1, UGT2B7,
UGT2B15,
Epoxide hydrolase
N/A
CYP1A2, CYP2B6,
CYP2C8, CYP2C9,
CYP2C19, CYP2E1,
CYP3A4, UGT, Epoxide
hydrolase
CYP1A2, CYP2B6,
CYP2C8, CYP2C9,
CYP2C19, CYP3A4,
UGTs, Epoxide hydrolase

None1

N/A

None1
None1

N/A
N/A

None1

N/A

Yes

CYP2C9, UGT1A4,
UGT2B7, Epoxide
hydrolase, Nglucosidation

Unclear

Second-Generation Antiepileptics
Eslicarbazepine
Weak
Felbamate
Weak
Gabapentin
None2
Lacosamide
None2
Lamotrigine
Weak
Levetiracetam
None2
Oxcarbazepine
Weak
Pregabalin
None2
Retigabine
None2
Rufinamide
Weak
Stiripentol
None2

CYP3A4
CYP3A4
N/A
N/A
UGT
N/A
CYP3A4, UGTs
N/A
N/A
CYP3A4, UGTs
N/A

CYP2C19
CYP2C19, -oxidation
N/A
N/A
N/A
N/A
CYP2C19
N/A
N/A
CYP2E1
CYP1A2, CYP2C19,
CYP2D6, CYP3A4
Tiagabine
None2
N/A
None1
N/A
Topiramate
CYP2C19
Weak
Weak
CYP3A4, -oxidation
Vigabatrin
None2
N/A
None
N/A
Zonisamide
None2
N/A
None1
N/A
CYP: cytochrome P450; N/A: not applicable; UGT: uridine diphosphate glucuronosyl transferase
1
None means that the antiepileptic is not a clinically relevant inhibitor. Antiepileptic drugs, as any substrate
(see Table 1), can behave as a competitive inhibitor and in rare circumstances this inhibition may have
clinical relevance.
2
None means that the antiepileptic is not a clinically relevant inducer.
Yes
Yes
None
None1
None1
None
Weak
None
None
Weak
Yes
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Table 4. Summary of pharmacokinetic drug interactions between antiepileptics and second-generation antipsychotics.
Antiepileptic
Antipsychotic
Effect
Proposed mechanism
Carbamazepine
Aripiprazole
Mean AUC decrease by 71% and 4-fold increase in clearance
CYP3A4 induction
Clozapine
Decrease in plasma clozapine concentrations by 50%
CYP1A2 and CYP3A4
induction
Olanzapine
Decrease in olanzapine dose-normalized concentrations by 36-71% CYP1A2 and UGT induction
Paliperidone
Decrease in steady-state Cmax and AUC of paliperidone by 37%
Renal P-gp induction
Quetiapine
Decrease of quetiapine peak plasma concentration (Cmax) by 80%,
CYP3A4 induction
AUC by 87% and a 7.5-fold increase of its oral clearance
Risperidone
Decrease in risperidone total active moiety concentrations by 50%
CYP3A4 induction
Ziprasidone
Decrease in ziprasidone AUC by 36%
CYP3A4 induction
Lamotrigine
Clozapine
No significant changes in plasma clozapine concentrations
Olanzapine
Moderate elevation of plasma olanzapine concentrations by 15%
UGT1A4 competitive inhibition
Quetiapine
Moderate decrease of plasma quetiapine concentrations by 17%
Risperidone
No significant changes in plasma risperidone concentrations
Oxcarbazepine
Clozapine
No significant changes in plasma concentrations of antipsychotics
Olanzapine
Risperidone
Phenobarbital
Clozapine
Decrease in plasma clozapine concentrations by 35%
CYP1A2, CYP3A4 and UGT
induction
Phenytoin
Quetiapine
Decrease by 80% of plasma quetiapine concentrations and 5-fold
CYP3A4 induction
increase of its clearance
Topiramate
Clozapine
No significant changes in plasma concentrations of antipsychotics
Olanzapine
Quetiapine
Risperidone
Valproic acid
Aripiprazole
Decrease in plasma aripiprazole concentrations by 24%
CYP3A4 and/or gastrointestinal
P-gp induction
Clozapine
Variable results reported with plasma clozapine concentrations
slightly increased, slightly decreased or unchanged
Olanzapine
Decrease in plasma olanzapine concentrations by 18-50%
CYPs and/or UGT induction
Quetiapine
No significant changes in plasma quetiapine concentrations
Risperidone
No significant changes in plasma risperidone concentrations
AUC: area under the curve; CYP: cytochrome P450; P-gp: P-glycoprotein; UGT: uridine diphosphate glucuronosyl transferase.
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Table 5. Practical summary of antiepileptic and second-generation antipsychotic drug interactions
ANTIEPILEPTICS
SGAPs
OUTCOME
PK DI. Powerful inducers:
A.↓level 2-4 wks after adding inducer
carbamazepine, phenobarbital quetiapine, lurasidone?>1
↑level 2-4 wks after D/C inducer
2 1
phenytoin, primidone
olanzapine, clozapine >
aripiprazole,iloperidone, risperidone>1
asenapine? >1
amisulpride, paliperidone, ziprasidone Not relevant
PK DI. Mild inducers:3
↓mild level 2-4 wks after adding inducer
quetiapine, lurasidone?>1
eslicarbazepine, felbamate,
↑mild level 2-4 wks after D/C inducer
olanzapine, clozapine 2>1
oxcarbazepine,4 topiramate,4 aripiprazole,iloperidone,risperidone>1
rufinamide
asenapine? >1
PK DI. valproate
olanzapine,
↓ mild level
clozapine 2
mild ↓ or ↑ level
PD DI. valproate
SGAP
↑ efficacy in mania/maintenance5
PD DI.
FGAEDs, topiramate >1
Other
Absence of PD DI.
felbamate, lacosamide,
lamotrigine, tiagabine
PD DI.
carbamazepine, gabapentin
pregabalin, valproate
PD DI.
topiramate, zonisamide7
PD DI. AEDs
PD DI. carbamazepine,
phenobarbital, phenytoin,
primidone >1
oxacarbazepine, valproate
PD DI. valproate rarely9
PD DI.
carbamazepine very rarely
PD DI. valproate rarely
PD DI.
topiramate, zonisamide rarely

clozapine, asenapine,olanzepine>
quetiapine>
Other
aripiprazole, ziprasidone

Additive sedation risk

ACTIONS
A. In absence of TDM use correction factor:
52
2-4
2
Unknown
Possibly no clinically relevant changes
A. Monitor for ↓ efficacy after adding inducer
B. Monitor for ADRs after discontinuing inducer

A. Be aware
Can’t rule out occasional clinical relevance
A. Be aware
B. Monitor for ADRs
A. Monitor for sedation

These AEDs and SGAPs may not be
sedating

Be aware

clozapine, olanzapine >1
asenapine, paliperidone, quetiapine,
risperidone>1
amisulpride, aripiprazole, iloperidone,
lurasidone, ziprasidone
SGAPs

Additive weight gain risk

A. Monitor weight
B. Monitor serum glucose and lipids6

Weight loss

Be aware

SGAPs

Additive impaired swallowing risk8

amisulpride, paliperidone, risperidone

Possible additive osteoporosis risk

Monitor closely in patients with intellectual
disability or dementia
Monitor closely

SGAPs more rarely10

Possible additive pancreatitis risk

A. Be vigilant (can be lethal)

clozapine rarely
SGAPs rarely
SGAPs rarely ↑ risk with
anticholinergic drugs11

Both have risk for agranulocytosis
Both associated with leucopenia
Both associated with heat stroke

DO NOT COMBINE
A. Be vigilant (can be lethal)
In elderly and/or exposed to strenuous exercise/
high temperatures:
A. Be vigilant (can be lethal):
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B. Encourage proper hydration.

ADR: adverse drug reaction; AED: antiepileptic drug; FGAED: first-generation antiepileptic drug; PD DI: pharmacodynamic drug interaction;
PK DI: pharmacokinetic drug interaction; SGAP: second-generation antipsychotic; SGAED: second-generation antiepileptic drug; ?: reflects
that information on asenapine and lurasidone is limited. It is likely that asenapine may be influenced by potent inducers but it has not been
studied.
1
Drugs preceding ">" will produce a more powerful outcome than the drugs listed on the following line.
2
Please be aware that a correction factor of 5 was suggested by a phenytoin pharmacokinetic study by Wong et al. [80], but a correction factor
of 7.5 was suggested by a carbamazepine pharmacokinetic study [56]. Rifampin, a CYP3A4 inducer, increased lurasidone metabolism by a
factor of 5.
3
The risk of SGAP-induction reflects what we know from powerful AED inducers.
3
High doses of oxcarbazepine (≥ 1500 mg/d) or TMP (≥ 200 mg/d).
5
The combination of valproate with SGAPs may be more effective than monotherapy. This is particularly well established in mania; this type of
combination for bipolar maintenance is standard clinical practice. As far as we know, there is no such data for additive effects for the
combination of carbamazepine with SGAPs but this combination is frequently recommended for maintenance by pharmacological guidelines.
Any study trying to establish the additive effects of carbamazepine and SGAPs in bipolar disorder will need to correct for pharmacokinetic DIs.
6
Serum glucose and lipid abnormalities may be associated with weight gain. Drugs can also produce direct effects on glucose and/or lipid
metabolism. Clozapine, olanzapine and quetiapine have been definitively associated with hyperglycemia and hyperlipidemia independent of
weight gain. Carbamazepine has been associated with increases in total cholesterol and high density lipoprotein (HDL) cholesterol. Some
studies have associated phenytoin with hyperglycemia and increases in total cholesterol. Valproate has been associated with lower total
cholesterol, which may be positive, but is also associated with lowering HDL and insulin resistance.
7
Felbamate is associated with weight loss but it cannot be used for that indication due to its high risk for severe ADRs.
8
Although it has not been studied: i) all SGAPs can interfere with swallowing and cause esophageal dysmotility, ii) AEDs can also interfere
with swallowing, and iii) additive or synergistic pharmacodynamic DIs upon swallowing are likely.
9
Valproate is definitively associated with pancreatitis but the mechanism is not known.
10
Rarely, SGAPs have been associated with pancreatitis, but the connection is not completely established. Some of these cases of pancreatitis
were associated with hypertriglyceridemia, which is a known risk factor for pancreatitis. Clozapine, olanzapine and quetiapine have been
definitively associated with hyperlipidemias that can occur in the absence of obesity and are probably explained by the direct effects of the
drugs on lipid metabolism.
11
Clozapine, olanzapine and high doses of quetiapine have anticholinergic (antimuscarinic) activity. Antiparkinsonian drugs can be coprescribed with SGAPs and have high anticholinergic (antimuscarinic) activity.

